HBM Holdings Limited (02142.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 12.91

From 52W high−18.36%

Volume15.47M

Market capHKD 11.12B

P/E (TTM)14.9x

P/S (TTM)9.0x

Div yield—

Key dataSep 18, 2026

Open

HKD 12.91

From 52W high

−18.36%

Volume

15.47M

Market cap

HKD 11.12B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

13.8x

P/E (TTM)

14.9x

RSI (14)

50.6

MomentumView details →

1D Return

+10.63%

YTD Return

+15.54%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

14.9x

EV/EBITDA

13.8x

EV/Sales

7.3x

P/S (TTM)

9.0x

P/B (TTM)

3.4x

ProfitabilityView details →

Gross Margin

93.00%

Net Margin

57.81%

EBITDA Margin

52.61%

ROE (TTM)

21.89%

ROA (TTM)

17.15%

Asset Turnover

0.31x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+57.29%

EPS CAGR 3Y

+97.71%

EBITDA YoY

—

MomentumView details →

1D Return

+10.63%

YTD Return

+15.54%

1Y Return

−8.53%

RSI (14)

50.6

vs 50D SMA

+2.25%

vs 200D SMA

+10.40%

Capital & dividendView details →

Debt/Equity

0.21x

Current Ratio

4.90x

Quick Ratio

4.84x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

HKD 0.63

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

0.18%

Financials snapshotView financials →

Revenue (TTM)

244.02M

Net Income (TTM)

121.59M

Op. CF (TTM)

516.09M

Next earningsMar 31, 2027 →

Latest newsMore news →

Solstice Oncology completed a $225 million Series A financing led by RA Capital Management, with participation from Canaan Partners, Forbion and other investors, and launched operations.11d ago

Harbour BioMed announced its interim results for the six months ended June 2026, with revenue of $122 million, up 20.9% year-on-year, and net profit of $64.88 million, down 9.5%.24d ago

Similar companies

Nanjing Leads Biolabs Co Ltd09887.HK 欧林生物688319.SH Bio-Techne CorporationTECH Axsome Therapeutics, Inc.AXSM Mabwell-b02493.HK 诺唯赞688105.SH Find similar companies →

Latest newsMore news →

Solstice Oncology completed a $225 million Series A financing led by RA Capital Management, with participation from Canaan Partners, Forbion and other investors, and launched operations.11d ago Harbour BioMed announced its interim results for the six months ended June 2026, with revenue of $122 million, up 20.9% year-on-year, and net profit of $64.88 million, down 9.5%.24d ago